Cartesian Therapeutics In

RNAC10 Dec 2024
Healthcare
$25
+0.02 (+1.71%)
Lowest Today
$24.88
Highest Today
$26.13
Today’s Open
$25
Prev. Close
$25.14
52 Week High
$41.87
52 Week Low
$11.67
To Invest in Cartesian Therapeutics In

Cartesian Therapeutics In

Healthcare
RNAC10 Dec 2024
+0.02 (+1.71%)
1M
3M
6M
1Y
5Y
Low
$24.88
Day’s Range
High
$26.13
24.88
52 Week Low
$11.66
52-Week Range
52 Week High
$41.87
11.66
1 Day
-
1 Week
+26.43%
1 month return
+23%
3 month return
+88.73%
6 month return
-23.35%
1 Year return
+14.19%
3 Years return
-73.66%
5 Years return
-46.3%
10 Years return
-
Institutional Holdings
FMR Inc
11.22
Fidelity Select Biotechnology
2.57
MPM Oncology Impact Management LP
2.48
HBM Healthcare Investments AG Ord
1.62
BlackRock Inc
1.6
Citadel Advisors Llc
1.48
JPMorgan Chase & Co
1.22

Market Status

Fundamentals
Market Cap
430.27 mln
PB Ratio
849.64
PE Ratio
0
Enterprise Value
434.38 mln
Total Assets
305.05 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
Organisation
Cartesian Therapeutics In
Employees
37
Industry
Biotechnology
CEO
Dr. Carsten  Brunn Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities